{"brief_title": "Study Evaluating CCI-779 in Active Rheumatoid Arthritis on Concomitant Methotrexate Therapy", "brief_summary": "The primary objective of this study is to compare the therapeutic response and safety of 3 oral dose levels of CCI-779, with placebo in subjects with active rheumatoid arthritis (RA) who have been receiving stable doses of methotrexate (MTX) for at least 8 weeks.", "condition": ["Rheumatoid Arthritis"], "intervention_type": ["Drug", "Drug"], "intervention_name": ["CCI-779", "Placebo"], "arm_group_label": ["A", "B", "C", "D"], "criteria": "Inclusion Criteria: - Meet American College of Rheumatology (ACR) criteria for RA - Have active RA consisting of \u2265 6 swollen and \u2265 6 painful joints - ACR functional class I-III Exclusion Criteria - At screening the subject's prior medications are reviewed. (Prior history of disease-modifying antirheumatic drug (DMARD) use is recorded, including the start and stop dates of the most recently taken DMARDs) - Significant concurrent medical diseases - Abnormal chest radiograph, including findings consistent with interstitial pneumonitis, granulomatous disease, or pleural effusion and/or infiltration", "gender": "All", "minimum_age": "18 Years", "maximum_age": "75 Years", "healthy_volunteers": "No", "mesh_term": ["Arthritis", "Arthritis, Rheumatoid", "Methotrexate", "Everolimus", "Sirolimus"], "id": "NCT00076206"}